Multidisciplinary Management of Lung Cancer

Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy

“…Lung cancer is the most common malignancy in many countries and it has become the number one cause of cancer death in Korea, surpassing gastric cancer [1,2]. The majority of lung cancer patients have non-small cell type and locally advanced unresectable nonsmall cell lung cancer (NSCLC) represents approximately 35-40% of newly diagnosed cases of NSCLC [2].…”

“…The majority of lung cancer patients have non-small cell type and locally advanced unresectable nonsmall cell lung cancer (NSCLC) represents approximately 35-40% of newly diagnosed cases of NSCLC [2].…”

“…Concurrent chemoradiotherapy (CCRT) is now established as a standard treatment for locally advanced unresectable NSCLC; it has better survival compared to radiotherapy (RT) alone or induction chemotherapy followed by RT [2][3][4][5]. However, despite the advances in CCRT, the overall outcome of locally advanced NSCLC is still poor, with median survival of 12-24 months and a small proportion of long term survivors [2][3][4][5].…”

“…However, despite the advances in CCRT, the overall outcome of locally advanced NSCLC is still poor, with median survival of 12-24 months and a small proportion of long term survivors [2][3][4][5]. Therefore, the determination of parameters that may identify those patients who would benefit from the specific treatment has strong clinical implications.…”

Cancer pulmonaire

“…La stimulation de TLR7 et TLR8 induit une résistance à la chimiothérapie Les patients atteints de cancer pulmonaire sont souvent traités par polychimiothéra-pie associant des sels de platine avec une drogue de deuxième génération comme la navelbine [11]. Nous avons émis l'hypothèse que la stimulation des TLR7 et TLR8 exprimés par les cellules tumorales pouvait induire un état de résistance à la mort cellulaire induite par les drogues utilisées en chimiothérapie.…”